重药控股7家子公司补缴税款滞纳金3221万元

Group 1 - The core point of the news is that Chongqing Pharmaceutical Holdings (重药控股) disclosed that seven of its subsidiaries have paid a total of 32.21 million yuan in back taxes and late fees [1] - The seven subsidiaries involved are Qinghai Pharmaceutical Co., Ltd., Inner Mongolia Zhelimeng Pharmaceutical Co., Ltd., Guizhou Pharmaceutical Group Co., Ltd., Guizhou Pharmaceutical Group He Ping Pharmaceutical Co., Ltd., Shaanxi Huashi Pharmaceutical Co., Ltd., Shaanxi Pharmaceutical Co., Ltd., and Chongqing Pharmaceutical Group (Gansu) Co., Ltd. [1] - The company stated that the back taxes and late fees were due to the self-examination of the subsidiaries regarding the income tax benefits enjoyed under the Western Development policy, with 7.46 million yuan due for 2025 and 24.75 million yuan for 2026 [1] Group 2 - For the first three quarters of 2025, Chongqing Pharmaceutical Holdings reported an operating income of 62.2 billion yuan, representing a year-on-year increase of 4.22% [2] - The net profit attributable to shareholders of the listed company was 384 million yuan, showing a year-on-year growth of 31.41% [2]